The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 06, 2008
Filed:
Jul. 23, 2003
Julia Elizabeth Thompson, Herts, GB;
Tristan John Vaughan, Cambridge, GB;
Andrew James Williams, Fowlmere, GB;
Jonathan Alexander Green, Cambridgeshire, GB;
Ronald Henry Jackson, Cambridge, GB;
Louise Bacon, Cambs, GB;
Kevin Stuart Johnson, Cambs, GB;
Alison Jane Wilton, Cambridge, GB;
Philip Ronald Tempest, Cambridge, GB;
Raymond Paul Field, Hertfordshire, GB;
Steven Paul Ruddock, Cambridge, GB;
Gregory Paul Winter, Chulmleigh, GB;
Julia Elizabeth Thompson, Herts, GB;
Tristan John Vaughan, Cambridge, GB;
Andrew James Williams, Fowlmere, GB;
Jonathan Alexander Green, Cambridgeshire, GB;
Ronald Henry Jackson, Cambridge, GB;
Louise Bacon, Cambs, GB;
Kevin Stuart Johnson, Cambs, GB;
Alison Jane Wilton, Cambridge, GB;
Philip Ronald Tempest, Cambridge, GB;
Raymond Paul Field, Hertfordshire, GB;
Steven Paul Ruddock, Cambridge, GB;
Gregory Paul Winter, Chulmleigh, GB;
Cambridge Antibody Technology Limited, Cambridge, GB;
Medical Research Council, London, GB;
Abstract
Specific binding members comprising human antibody antigen binding domains specific for human transforming growth factor beta (TGFβ) bind specifically isoforms TGFβ2 and TGFβ1 or both, preferentially compared with TGFβ3. Specific binding members may be isolated and utilized in the treatment of disease, particularly fibrotic disease and also immune/inflammatory diseases. Therapeutic utility is demonstrated using in vitro and in vivo models. Full sequence and binding information is provided, including epitope sequence information for particularly advantageous specific binding member which binds the active form of TGFβ2, neutralizing its activity, but does not bind the latent member.